Thermo Fisher Scientific (TMO) has just posted its Q2 2026 numbers, with revenue of about US$12.0 billion and basic EPS of US$4.68 helping to shape how investors assess the latest half year, while trailing 12 month EPS sits at US$18.63 on revenue of roughly US$46.3 billion. Over the past few quarters, revenue has moved from US$10.9 billion in Q2 2025 to US$12.0 billion in Q2 2026, and quarterly basic EPS has shifted from US$4.28 to US$4.68. This sets up a results season where margins and earnings quality are front of mind for investors looking at this report.

See our full analysis for Thermo Fisher Scientific.

With the headline numbers on the table, the next step is to set these results against the widely followed narratives around Thermo Fisher Scientific to see which stories hold up and which need rethinking.

Thermo Fisher EPS Trend Backs Earnings Growth Story

• On a trailing 12 month basis, Thermo Fisher Scientific has basic EPS of US$18.63, up from US$17.10 at the start of 2025, while quarterly basic EPS in Q2 2026 of US$4.68 sits above Q1 2026 at US$4.44 and Q2 2025 at US$4.28.
• Supporters of the bullish narrative argue that earnings growth can compound over time, and the recent 5.8% trailing earnings growth versus a 5 year annualized decline of 4.3% directly speaks to that shift, even as:
  • Forecast earnings growth of about 10.5% per year is stronger than the roughly 5.3% revenue growth forecast, so bulls see scope for earnings to grow faster than sales if margins cooperate.
  • The current P/E of 30.3x sits below the cited 42.1x peer average and 36.6x Global Life Sciences average, which bullish investors often point to when arguing that stronger earnings could be supported by current pricing.

Bulls point to this earnings shift as a key proof point for their case, and the wider narrative lays out what they think could keep that momentum going over time. 🐂 Thermo Fisher Scientific Bull Case

Margins Around 15% Put Profit Quality In Focus

• Net income over the last 12 months sits at about US$7.0b on revenue of roughly US$46.3b, which translates into a trailing net profit margin of about 15% compared with 15.2% a year earlier.
• Skeptics focus on this small margin slip and the company’s high debt load when testing the bearish narrative, because:
  • The Analytical Instruments segment is described as under pressure in the bearish view, and a flat to slightly softer net margin around 15% can be read as leaving less room to absorb further cost or pricing headwinds.
  • Total debt of US$35.2b is highlighted in that same cautious view, and with margins not moving higher in the latest trailing period, bearish investors worry that servicing that debt could limit flexibility if growth slows.

Those concerns frame the more cautious storyline around Thermo Fisher Scientific, which digs into where bears think growth and margins could struggle from here. 🐻 Thermo Fisher Scientific Bear Case

Valuation Sits Between DCF Value And Analyst Target

• The current share price of US$568.26 is below the cited DCF fair value of about US$641.16 yet also sits below the 618.00 analyst price target, while the P/E ratio of 30.3x remains under both peer and industry averages.
• The consensus narrative tries to balance these signals, because:
  • A price below the DCF fair value and a P/E discount to peers can appeal to investors who think the current 15% margin and improving earnings trend justify a stronger valuation than today.
  • At the same time, the forecast that revenue could grow around 5.3% per year, which is below the cited 12.7% for the wider US market, plus the high debt level, helps explain why others are more cautious about assigning a higher multiple.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Thermo Fisher Scientific on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views around Thermo Fisher Scientific’s earnings, margins and valuation, this is the point where you pressure test the story yourself using the same numbers before sentiment shifts. To see how the current positives and concerns line up, start with the 2 key rewards and 1 important warning sign.

See What Else Is Out There

Thermo Fisher Scientific’s flat net margin around 15% alongside a sizeable US$35.2b debt load raises questions about balance sheet resilience if conditions become less supportive.

If that mix of steady earnings and high leverage leaves you cautious, compare it with companies in the solid balance sheet and fundamentals stocks screener (49 results), where stronger financial footing can help you sleep better at night.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.